TPA Slams CMS Final Rule Imposing Price Controls on Critical Drugs
Taxpayers Protection Alliance
November 17, 2026
FOR IMMEDIATE RELEASE
Contact: Kara Zupkus (224) 456-0257
WASHINGTON, D.C. – Today, the Taxpayers Protection Alliance (TPA) sharply criticized the Centers for Medicare & Medicaid Services (CMS) for finalizing a rule enacting heavy-handed price controls on lifesaving pharmaceuticals. Finalized on November 5, the rule pertains to Medicare’s Drug Price Negotiation Program for 2029 and beyond. Under the Inflation Reduction Act (IRA), drug manufacturers that refuse to participate in Medicare price negotiations or fail to agree to a “maximum fair price” face steep excise taxes on sales of the selected drug unless they withdraw all of their drugs from coverage under Medicare Part D’s Manufacturer Discount Program and the Medicaid Drug Rebate Program.
Ross Marchand, Executive Director of TPA, offered the following comment:
“Medicare price controls will do nothing to make drugs more affordable or accessible. Instead, they will mean fewer treatments for millions of patients. Bringing a medication to market typically takes more than a decade and up to $2 billion, and manufacturers will invest this time and money only if they can recoup these costs. These heavy-handed price controls effectively destroy the incentive to bring lifesaving new medications to market.
“Specifically, CMS’s decision to group innovative new versions of existing medicines under the same qualifying single-source drug (QSSD) for price negotiations further undermines these incentives, even when they require separate FDA approval and clinical trials. This misguided policy could discourage follow-on innovation that makes treatments safer, more convenient, and accessible for patients.
“Price controls have an abysmal track record of improving healthcare access. European countries, which rely heavily on drug and medical device price controls in their healthcare systems, have learned this lesson the hard way. Because of price controls, most hospital pharmacists in Europe have reported critical medicine shortages. Everything from antimicrobial agents to oncology medications to anesthetic agents is now harder to get because of heavy-handed government policies. Importing these policies into the U.S. is the wrong prescription for healthcare access.
“Policymakers must reverse these misguided price controls and allow patients to access lifesaving medications.”
###
The Taxpayers Protection Alliance (TPA) is a non-profit, non-partisan organization dedicated to educating the public through the research, analysis, and dissemination of information on the government’s impact on the economy.